270 related articles for article (PubMed ID: 29316837)
1. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.
Jagasia M; Zeiser R; Arbushites M; Delaite P; Gadbaw B; Bubnoff NV
Immunotherapy; 2018 Apr; 10(5):391-402. PubMed ID: 29316837
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib for the treatment of graft-versus-host disease.
Ali H; Salhotra A; Modi B; Nakamura R
Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
[No Abstract] [Full Text] [Related]
3. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
[TBL] [Abstract][Full Text] [Related]
10. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R; Polverelli N; Ram R; Hashmi SK; Chakraverty R; Middeke JM; Musso M; Giebel S; Uzay A; Langmuir P; Hollaender N; Gowda M; Stefanelli T; Lee SJ; Teshima T; Locatelli F;
N Engl J Med; 2021 Jul; 385(3):228-238. PubMed ID: 34260836
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
15. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
17. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
[TBL] [Abstract][Full Text] [Related]
19. [Ruxolitinib for treatment of GvHD in patients with myelofibrosis].
Mori Y
Rinsho Ketsueki; 2019; 60(8):953-959. PubMed ID: 31484895
[TBL] [Abstract][Full Text] [Related]
20. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]